The High Q Foundation and Stem Cell Innovations (SCI) have entered into a two-year R&D alliance. The organizations will apply SCI's PluriCells™ to develop Huntington's-disease-specific human cell systems for the purpose of drug discovery.
Under the terms of their agreement, SCI will receive up to $1.1 million from High Q upon completion of certain milestones. In addition, SCI has the right to further use, develop, and commercialize the outcome of the project.
"This agreement will allow us to accelerate our efforts in generating a unique panel of human neurodegenerative disease models, which will be integral in the further development of our potential products," says SCI CEO, James Kelly.